黑料网

Gynecologic cancers comprise a group of cancers that begin in the womanish reproductive organs. The 5 main types of gynecologic cancers are cervical, ovarian, uterine (endometrial cancer and uterine sarcoma), vaginal, and vulvar. Although they're frequently grouped together, each gynecologic cancer has distinct threat factors, signs and symptoms, prognostic, and complaint burden [1].

Frequency and prevalence of gynecologic cancers

The frequency, prevalence, and mortality rates for the gynecologic cancers vary across conditions. In 2014, gynecologic cancers reckoned for roughly 12 (out of) of all new cancer judgments in women in the United States. Of the 5 gynecologic cancers, there are roughly and women presently living with cervical and ovarian cancers, independently, in the United States. Ovarian and cervical cancers represent 1.3 and 0.7 of new cancer cases, independently, in US women. Age-acclimated prevalence rates per time grounded on cases diagnosed from 2006 through 2010 are 12.5 per persons for ovarian cancer and 7.9 per persons for cervical cancer [2].

Rates of ovarian cancer are loftiest in women age 55 to 64 times (median age at opinion 63 times) whereas rates of cervical cancer are loftiest in women 35 to 44 times old. Of note, the median age at opinion of cervical cancer is 49 years. White women have the loftiest prevalence of ovarian cancer and Hispanic women have the loftiest prevalence of cervical cancer, with roughly 13.3 and10.9 new cases per persons, respectively. In recent times, there has been a significant reduction in the prevalence of ovarian cancer that has coincided with the dropped use of menopausal hormone remedy, following the Women's Health Initiative report, which demonstrated that the health pitfalls overbalanced implicit benefits when hormone remedy was used to help habitual complaint in

healthy postmenopausal women. Over the once 30 times, the prevalence of cervical cancer has dropped further than 50, largely due to wide webbing with the Pap smear. The vacuity of two vaccines against mortal papilloma contagion (HPV) has led to a reduction in the frequence of HPV and will probably impact the burden of HPV- associated conditions, including cervical cancer. The prevalence rates of uterine, vaginal, and vulvar cancers have remained fairly stable over the last 10 times [3].

Mortality and survival rates for gynecologic cancers

Case survival rates vary across the different types of gynecologic cancers and are largely dependent on the stage at which a particular cancer is diagnosed. Five- time survival rates for the times 2003 to 2009 range from 44 for ovarian cancer to 69 for cervical cancer. It's important to note that the opinion for ovarian cancer tends to do in distant- stage complaint (roughly 61 of cases) when the cancer has metastasized. In these cases, 5-time survival is only 27, whereas, cases diagnosed with localized complaint have a prognosticated 5-time survival lesser than 90. Again, cervical cancer judgments tend to do before in the complaint process, with 47 of cases entering a opinion when cancer is localized to the primary point and 36 having complaint classified as indigenous. In these cases, 5- time survival rates are 91 and 57, independently. In general, mortality rates increase with age in women with ovarian cancer. Because ovarian cancer tends to develop in aged women, the median age at death is 71 times. The median age at death from cervical cancer is 57 years. Black women are further than doubly as likely to die from cervical cancer as white women [4, 5].

1. Hiluf S (2015)

,

2. ,
3. Lueth GD, Kebede A, Medhanyie AA (2020) BMC Pregnancy and Childbirth 20: 1-10.

,

4. Bekru ET, Yirdaw BE (2018) . Int J Nurs Midwifery 10: 161-167.

, ,

5. Abdulkadir Y, Dejene A, Geremew M, Dechasa B (2017) . Intern Med 7: 2.

, ,